Brandon Seaton
YOU?
Author Swipe
View article: Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs
Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs Open
Background The translational study of chimeric antigen receptor (CAR) T-cell function, persistence, immunophenotype, and spatial localization after infusion is crucial for understanding factors that influence clinical outcomes. However, re…
View article: Supplementary Data 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Data 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies Open
Supplementary Data 1: Study Protocol.
View article: Supplementary Figure 4 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 4 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies Open
Supplementary Figure 4: Flow cytometric analysis of T cell phenotypes in apheresis, infusion products and EGFRt + CAR T cells at peak of expansion.
View article: Supplementary Figure 2 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 2 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies Open
Supplementary Figure 2: Toxicity Assessment.
View article: Supplementary Table 2 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Table 2 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies Open
Supplementary Table 2: Patient and tumor characteristics.
View article: Supplementary Figure 3 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 3 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies Open
Supplementary Figure 3: Lymphodepletion and CAR T cell expansion.
View article: Supplementary Table 3 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Table 3 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies Open
Supplementary Table 3: Summary of adverse events Cohorts A and B, NCI CTCAE grading.
View article: Supplementary Figure 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Figure 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies Open
Supplementary Figure 1: Strobe Flow Diagram.
View article: Data from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Data from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies Open
Purpose:The receptor tyrosine kinase–like orphan receptor 1 (ROR1) is expressed in hematopoietic and epithelial cancers but has limited expression on normal adult tissues. This phase I study evaluated the safety of targeting ROR1 with auto…
View article: Supplementary Table 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Supplementary Table 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies Open
Supplementary Table 1: Representativeness of Study Participants.
View article: Spatial proteomics and transcriptomics characterization of tissue and multiple cancer types including decalcified marrow
Spatial proteomics and transcriptomics characterization of tissue and multiple cancer types including decalcified marrow Open
Background Recent technologies enabling the study of spatial biology include multiple high-dimensional spatial imaging methods that have rapidly emerged with different capabilities evaluating tissues at different resolutions for different …
View article: Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies Open
Purpose: The receptor tyrosine kinase–like orphan receptor 1 (ROR1) is expressed in hematopoietic and epithelial cancers but has limited expression on normal adult tissues. This phase I study evaluated the safety of targeting ROR1 with aut…
View article: Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses Open
Background Antibodies blocking programmed death (PD)-1 or its ligand (PD-L1) have revolutionized cancer care, but many patients do not experience durable benefits. Novel treatments to stimulate antitumor immunity are needed in the PD-(L)1 …
View article: Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma
Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma Open
Although immune check-point inhibitors (CPIs) revolutionized treatment of Merkel cell carcinoma (MCC), patients with CPI-refractory MCC lack effective therapy. More than 80% of MCC express T-antigens encoded by Merkel cell polyomavirus, wh…
View article: qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue
qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue Open
As adoptive cellular therapies become more commonplace in cancer care, there is a growing need to monitor site-specific localization of engineered cells—such as chimeric antigen receptor T (CAR-T) cells and T-cell receptor T (TCR-T) cells—…
View article: Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity Open
Background The paucity of tumor-specific targets for chimeric antigen receptor (CAR) T-cell therapy of solid tumors necessitates careful preclinical evaluation of the therapeutic window for candidate antigens. Human epidermal growth factor…
View article: 768 Transcriptional profiling of Merkel cell carcinoma that escaped polyomavirus-specific TCR-engineered T cells reveals actionable immunotherapy approaches
768 Transcriptional profiling of Merkel cell carcinoma that escaped polyomavirus-specific TCR-engineered T cells reveals actionable immunotherapy approaches Open
Background Checkpoint inhibitors (CPIs) have revolutionized treatment for Merkel cell carcinoma (MCC) patients. However, about 50% of patients fail to respond, or relapse, necessitating alternative therapies. More than 80% of MCC cases are…
View article: 93 PCR assay to identify woodchuck hepatitis virus posttranscriptional regulatory element in CAR-T and TCR-T cells for fresh and formalin-fixed samples
93 PCR assay to identify woodchuck hepatitis virus posttranscriptional regulatory element in CAR-T and TCR-T cells for fresh and formalin-fixed samples Open
Background Chimeric antigen receptor T-cell (CART) and engineered T-cell receptor cytotoxic T cell (TCRT) therapy are adoptive cellular therapies developed by modifying T-cells to target surface antigens of cancer cells in CART, and both c…
View article: AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker
AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker Open
To investigate aldo–keto reductase 1C3 (AKR1C3) expression in T and B acute lymphoblastic leukemia/lymphoma (ALL) patients. Three commercial antibodies were evaluated for AKR1C3 immunohistochemistry (IHC) staining performance: Polyclonal T…
View article: AKR1C3 Expression in T and B Acute Lymphoblastic Leukemia/Lymphoma for Clinical Use as a Biomarker
AKR1C3 Expression in T and B Acute Lymphoblastic Leukemia/Lymphoma for Clinical Use as a Biomarker Open
Objectives: To investigate aldo–keto reductase 1C3 (AKR1C3) expression in T and B acute lymphoblastic leukemia/lymphoma (ALL) patients. Methods: Three commercial antibodies were evaluated for AKR1C3 immunohistochemistry (IHC) staining perf…
View article: 1203 STING/type i interferon pathway activation in patients with perniosis during the COVID–19 pandemic
1203 STING/type i interferon pathway activation in patients with perniosis during the COVID–19 pandemic Open
Background During the COVID-19 pandemic, a high incidence of patients with perniosis was observed worldwide. Classically, perniosis is secondary to cold exposure, hemoproliferative and autoimmune diseases. Although the pathomechanism of pe…